A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patients tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications.
